These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 2994998

  • 1. Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF): discovery of (N-Ac-Tyr1, D-Arg2)-GRF(1-29)-NH2 as a GRF antagonist on membranes.
    Robberecht P, Coy DH, Waelbroeck M, Heiman ML, de Neef P, Camus JC, Christophe J.
    Endocrinology; 1985 Nov; 117(5):1759-64. PubMed ID: 2994998
    [Abstract] [Full Text] [Related]

  • 2. Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist.
    Waelbroeck M, Robberecht P, Coy DH, Camus JC, De Neef P, Christophe J.
    Endocrinology; 1985 Jun; 116(6):2643-9. PubMed ID: 2859987
    [Abstract] [Full Text] [Related]

  • 3. Comparative structural requirements of thirty GRF analogs for interaction with GRF- and VIP receptors and coupling to adenylate cyclase in rat adenopituitary, liver and pancreas.
    Robberecht P, Waelbroeck M, Coy D, De Neef P, Camus JC, Christophe J.
    Peptides; 1986 Jun; 7 Suppl 1():53-9. PubMed ID: 3018703
    [Abstract] [Full Text] [Related]

  • 4. Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and intestinal VIP receptors from rat and human: evidence that Ac-Tyr1hGRF is a competitive VIP antagonist in the rat.
    Laburthe M, Couvineau A, Rouyer-Fessard C.
    Mol Pharmacol; 1986 Jan; 29(1):23-7. PubMed ID: 3003561
    [Abstract] [Full Text] [Related]

  • 5. Blockade of growth hormone-releasing factor (GRF) activity in the pituitary and hypothalamus of the conscious rat with a peptidic GRF antagonist.
    Lumpkin MD, McDonald JK.
    Endocrinology; 1989 Mar; 124(3):1522-31. PubMed ID: 2537185
    [Abstract] [Full Text] [Related]

  • 6. Potent long-acting alkylated analogs of growth hormone-releasing factor.
    Murphy WA, Coy DH.
    Pept Res; 1988 Mar; 1(1):36-41. PubMed ID: 2908793
    [Abstract] [Full Text] [Related]

  • 7. Identification of receptor-binding pharmacophores of growth-hormone-releasing factor in rat adenopituitary.
    Lefrançois L, Gaudreau P.
    Neuroendocrinology; 1994 Apr; 59(4):363-70. PubMed ID: 8202217
    [Abstract] [Full Text] [Related]

  • 8. The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3',5'-monophosphate accumulation in rat primary pituitary cell culture.
    Cheng K, Chan WW, Barreto A, Convey EM, Smith RG.
    Endocrinology; 1989 Jun; 124(6):2791-8. PubMed ID: 2541999
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro.
    Rekasi Z, Varga JL, Schally AV, Halmos G, Groot K, Czompoly T.
    Proc Natl Acad Sci U S A; 2000 Feb 01; 97(3):1218-23. PubMed ID: 10655511
    [Abstract] [Full Text] [Related]

  • 14. Role of selected endogenous peptides in growth hormone-releasing hexapeptide activity: analysis of growth hormone-releasing hormone, thyroid hormone-releasing hormone, and gonadotropin-releasing hormone.
    Bercu BB, Yang SW, Masuda R, Walker RF.
    Endocrinology; 1992 May 01; 130(5):2579-86. PubMed ID: 1315249
    [Abstract] [Full Text] [Related]

  • 15. Interaction of vasoactive intestinal peptide (VIP) and N-terminally modified VIP analogs with rat pancreatic, hepatic and pituitary membranes.
    Robberecht P, Coy DH, De Neef P, Camus JC, Cauvin A, Waelbroeck M, Christophe J.
    Eur J Biochem; 1986 Aug 15; 159(1):45-9. PubMed ID: 3017717
    [Abstract] [Full Text] [Related]

  • 16. Characterization of VIP receptor-effector system antagonists in rat and mouse peritoneal macrophages.
    Pozo D, Montilla ML, Guerrero JM, Calvo JR.
    Eur J Pharmacol; 1997 Mar 05; 321(3):379-86. PubMed ID: 9085051
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone.
    Zarandi M, Horvath JE, Halmos G, Pinski J, Nagy A, Groot K, Rekasi Z, Schally AV.
    Proc Natl Acad Sci U S A; 1994 Dec 06; 91(25):12298-302. PubMed ID: 7991622
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.